

1 **Adherence to a healthful plant-based diet and risk of**
2 **mortality among individuals with chronic kidney disease: A**
3 **prospective cohort study**

4 ***Running Title: Plant-based diets and mortality in CKD***

5

6 **Alysha S. Thompson¹, Martina Gaggi², Nicola P. Bondonno^{1,3,4}, Amy Jennings¹, Joshua K.**
7 **O'Neill¹, Claire Hill⁵, Nena Karavasiloglou^{6,7,8}, Sabine Rohrmann^{6,7}, Aedín Cassidy^{1*} and**
8 **Tilman Kühn^{1,2,9*}**

9

10 ¹The Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast,
11 Northern Ireland, UK

12 ²Medical University of Vienna, Center for Public Health, Public Health Nutrition, Vienna, Austria

13 ³Danish Cancer Institute, Copenhagen, Denmark

14 ⁴Nutrition & Health Innovation Research Institute, School of Medical and Health Sciences, Edith
15 Cowan University, Joondalup, WA, Australia

16 ⁵Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom

17 ⁶Division of Chronic Disease Epidemiology; Epidemiology, Biostatistics and Prevention Institute
18 (EBPI), University of Zurich, Zurich, Switzerland

19 ⁷Cancer Registry of the Cantons Zurich, Zug, Schaffhausen and Schwyz, Institute of Pathology and
20 Molecular Pathology, University Hospital Zurich, Zurich, Switzerland

⁸European Food Safety Authority, Parma, Italy

21 ⁹University of Vienna, Department of Nutritional Sciences, Vienna, Austria

22

23 ***Correspondence:** t.kuhn@qub.ac.uk and a.cassidy@qub.ac.uk

24 **Corresponding Authors:** Prof Dr Tilman Kuhn and Prof Aedín Cassidy

25 Queen's University Belfast

26 Institute for Global Food Security (IGFS) / School of Biological Sciences

27 19 Chlorine Gardens

28 Belfast BT9 5DL

29 UK

30 Email: t.kuhn@qub.ac.uk

31 Telephone: +44 28 9097 1387

32 **Funding Source:** Alysha S. Thompson holds a PhD studentship of the Department for the Economy
33 (DfE), Northern Ireland.

34 **Word count:** 3,583

35

36

37

38

39

40

41

42

43

44

45

46

47

48 **Abstract**

49 **Background:** Plant-rich dietary patterns may protect against negative health outcomes
50 among individuals with chronic kidney disease (CKD), although aspects of plant-based diet
51 quality have not been studied. This study aimed to examine associations between healthful
52 and unhealthful plant-based dietary patterns with risk of mortality among CKD patients for
53 the first time.

54 **Methods:** This prospective analysis included 4,807 UK Biobank participants with CKD at
55 baseline. We examined associations of adherence to both the healthful plant-based diet
56 index (hPDI) and unhealthful plant-based diet index (uPDI), calculated from repeated 24-
57 hour dietary assessments, with risk of mortality using multivariable Cox proportional hazard
58 regression models.

59 **Results:** Over a 10-year follow-up, 675 deaths were recorded. Participants with the highest
60 hPDI scores had a 33% lower risk of mortality [HR_{Q4vsQ1} (95% CI): 0.67 (0.53-0.84), $p_{\text{trend}} =$
61 <0.001], while those with the highest uPDI scores had a 49% higher risk [1.49 (1.18-1.89),
62 $p_{\text{trend}} = 0.004$], compared to participants with the lowest respective scores and following
63 adjustment for other dietary and lifestyle factors. In food group-specific analyses, higher
64 wholegrain intakes were associated with a 29% lower mortality risk, while intakes of refined
65 grains, and sugar-sweetened beverages were associated a 28% and 31% higher risk,
66 respectively.

67 **Conclusions:** In CKD patients, a higher intake of healthy plant-based foods was associated
68 with a lower risk of mortality, while a higher intake of unhealthy plant-based foods was
69 associated with a higher risk. These results underscore the importance of plant food quality

70 and support the potential role of healthy plant food consumption in the treatment and
71 management of CKD to mitigate unfavourable outcomes.

72 **Key words:** Plant-based diet index; chronic kidney disease; management of CKD; mortality

73 **1. Introduction**

74 Chronic kidney disease (CKD) poses a significant global public health challenge. The number
75 of CKD-attributed deaths has increased by 98% from 1990 to 2016 (~0.6 million to ~1.2
76 million deaths), with projections that CKD will rank fifth among the leading causes of death
77 by 2040 (1-3). Further, the burden of disability-adjusted life-years (DALYs) attributed to CKD
78 has risen from 29th in 1990 to the 18th in 2019 (4). CKD is a progressive and comorbid
79 condition, often leading to end-stage kidney disease (ESKD), necessitating kidney
80 replacement therapy such as dialysis or transplantation (3, 5, 6). Notably, CKD stands out as
81 one of the few non-communicable diseases to sustain a continual increase in associated
82 mortality over the past two decades (1). Given CKD's substantial impact on the economy (7)
83 and on quality of life (8), there is a pressing need to explore how dietary and lifestyle
84 modifications can preserve kidney function and improve outcomes in CKD patients.

85 A plant-based diet (PBD) including lower amounts of animal-based foods has previously
86 been shown to be associated with better outcomes e.g., improved insulin sensitivity and
87 lower blood pressure and survival in individuals living with CKD (9-12). Previously, a diet
88 promoting solely plant proteins was criticised for enhancing protein-energy wasting and
89 malnutrition, especially in patients with CKD stage 5, however, more recent studies suggest
90 that plant-based proteins are both nutritionally adequate and beneficial for CKD patients
91 (13). Further, vegetarian, and vegan diets are now increasingly used to facilitate better
92 adherence to the 2020 Kidney Disease Outcomes Quality Initiative (KDOQI) nutrition

93 guideline which advises patients with earlier stages of CKD to lower dietary protein intake to
94 mitigate further kidney damage caused by glomerular hyperfiltration (14, 15).

95 While dietary modification to treat and manage CKD has a long tradition (16-18), the
96 relationship between PBD quality in the form of healthful and unhealthful plant-based
97 dietary patterns with risk of mortality in patients with early-stage CKD is unknown.

98 Therefore, this study aims to investigate the relationship between plant-based diet indices
99 (PDIs) and the risk of all-cause mortality among individuals with CKD using data from the UK

100 Biobank cohort.

101

102

103

104

105

106

107

108

109

110

111

112

113

114 **2. Methods**

115 **2.1 Study population**

116 The UK Biobank is a large cohort study of over 500,000 middle-aged adults recruited
117 between 2006-2010 from the United Kingdom. Participants were recruited across 22 study
118 centres in England, Scotland and Wales and provided baseline data by completing
119 touchscreen questionnaires, verbal interviews and undergoing physical and biological
120 assessments (19). The UK Biobank was approved by the NHS North West Multicentre
121 Research Ethics Committee (Ref. 11/NW/0382). All study participants provided written
122 informed consent at recruitment.

123 For this study, 502,236 participants were screened for a prior diagnosis of CKD and available
124 data from at least one valid 24-hr dietary assessment. Participants who withdrew their
125 consent during follow-up, had implausible energy intakes ($>17,573\text{KJ}$ or $< 3,347\text{KJ}$ for men
126 and $> 14,644\text{KJ}$ or $< 2,092\text{KJ}$ for women (20)), had missing covariate information, or their
127 follow-up ended before completing the final 24-hr dietary assessment were excluded from
128 this study. Of the 31,556 UK Biobank participants with CKD, 4,807 completed at least 1
129 dietary assessment and were included in the present analyses (**Supplementary Figure S1**).

130 **2.2 Dietary assessment**

131 Dietary intake was measured using the Oxford WebQ, a self-administered and internet-
132 based 24-hr dietary assessment tool. The Oxford WebQ assessment was issued on five
133 separate occasions: once during the recruitment phase as part of the baseline assessment at
134 the study centre (April 2009 – September 2010), and then on four further instances via
135 home computer outside of the recruitment period (February 2011 – June 2012). Between
136 April 2009 and June 2012, a minimum of 1 and a maximum of 5 assessments were

137 completed. Mean (SD) duration (years) between baseline (cycle 0) and first (cycle 1) and last
138 (cycle 4) dietary assessments were 1.6 (1.4) and 2.3 (1.4), respectively. Further details on
139 the Oxford WebQ have been documented elsewhere (21). The reliability of the Oxford
140 WebQ is supported by validation studies (22-24).

141 **2.3 Plant-based diet indices**

142 Following methods described previously (25-27), the Oxford WebQ tool was used to
143 construct a healthful plant-based diet index (hPDI) and unhealthful plant-based diet index
144 (uPDI); an established scoring tool used to assess the overall adherence to a PBD,
145 considering the quality of plant food consumption. To calculate the indices, 17 food groups
146 were used (whole grains, fruits, vegetables, nuts, legumes and vegetarian protein
147 alternatives, tea and coffee, fruit juices, refined grains, potatoes, sugar-sweetened
148 beverages (SSBs), sweets and desserts, animal fat, dairy, eggs, fish or seafood, meat, and
149 miscellaneous animal-based foods). Unlike previous studies where vegetable oils were
150 included as a 'healthy' food component, data on vegetable oils was not available for this
151 study. For the hPDI, healthy plant-food groups were scored positively, and unhealthy plant-
152 food groups and animal-derived food groups were scored in the reverse. For the uPDI,
153 positive scores were assigned to unhealthy plant-food groups and reverse scores were given
154 to healthy plant-food groups and animal-derived food groups. For each food group, intakes
155 of more than zero servings were ranked into sex-specific quartiles. For positive scores,
156 participants were assigned a score between 2 and 5 (2 for the lowest quartile of intake and
157 5 for the highest). Participants who reported zero intakes were assigned a score of 1. The
158 pattern of scoring was inverted for reverse scores. The scores assigned to each of the 17
159 food groups were summed to obtain the final hPDI and uPDI.

160 **2.4 Ascertainment of chronic kidney disease**

161 CKD cases were considered prevalent if diagnosed before the first dietary assessment via
162 self-reported or hospital inpatient data. CKD cases were defined using the International
163 Classification of Diseases, 10th Revision (ICD-10) codes (ICD-10 codes: N03, N06, N08, N11,
164 N12, N13, N14, N15, N16, N18, N19, Z49, I12, I13) or Office of Population Censuses and
165 Surveys Classification of Interventions and Procedures-version 4 (OPCS-4) codes in Hospital
166 Inpatient data (OPCS-4 codes: L74.1-L74.6, L74.8, L74.9, M01.2, M01.3-M01.5, M01.8,
167 M01.9, M02.3, M08.4, M17.2, M17.4, M17.8, M17.9, X40.1-X40.9, X41.1, X41.2, X41.8,
168 X41.9, X42.1, X42.8, X42.9, and X43.1). Further information regarding the codes used to
169 define CKD can be found in **Supplement Table S1**. Using serum creatinine, the CKD-EPI
170 (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation (28) was used to
171 calculate glomerular filtration rate. Participants with a baseline estimated glomerular
172 filtration rate (eGFR) <60ml/min/1.73m² were considered as having CKD.

173 **2.5 Ascertainment of mortality**

174 The primary outcome of this study was all-cause mortality. Death data was obtained from
175 death certificates provided by the National Health Service England (England and Wales) and
176 National Health Service Central Register, National Records of Scotland (Scotland). Mortality
177 data was available until 30th November 2022 for England, Scotland, and Wales. Follow-up
178 time was calculated from the date of the last dietary assessment and was censored at date
179 of death, lost to follow-up, or death registry censoring date, whichever was the earliest.

180 **2.6 Assessment of covariates**

181 Between 2006 and 2010, participants provided information on sociodemographic, dietary,
182 lifestyle and medical history at the assessment centre, where several types of assessments

183 were performed. A touchscreen questionnaire was used to collect information on self-
184 reported age, sex, ethnicity, smoking status, education level and physical activity at
185 baseline. Multimorbidity was identified through data on past and current medical conditions
186 obtained through verbal interview at the initial assessment. Polypharmacy was also
187 obtained through verbal interview at baseline and was defined by the number of self-
188 reported treatments/medications taken. Prevalent diabetes was defined through self-
189 reporting at the touchscreen questionnaire and verbal interview. Townsend deprivation
190 index was calculated at baseline using postcodes of residence. Physical measures including
191 waist circumference, height, and weight were manually obtained at the initial assessment
192 by trained professionals. Height and weight were used to calculate body mass index (BMI),
193 dividing weight (kg) by the square of height (m). Number of completed dietary assessments,
194 energy, alcohol, and protein intake was based on the 24-hr Oxford WebQ dietary
195 questionnaire. To calculate eGFR, the CKD-EPI (Chronic Kidney Disease Epidemiology
196 Collaboration) creatinine equation (28) was employed using serum creatinine which was
197 measured by enzymatic analysis on a Beckman Coulter AU5800.

198 **2.7 Assessment of genetic risk score of eGFR**

199 A detailed description of the genotyping, imputation, and quality control of the UK Biobank
200 genetic data has been published previously (29). A recent GWAS by Wuttke et al. 2019 was
201 used to identify single nucleotide polymorphisms (SNPs) associated with CKD. Using a
202 weighted method, a polygenic risk score (PRS) of eGFR was calculated using 161 SNPs
203 (**Supplementary Table S2**). A higher PRS of eGFR indicates a lower genetic risk of kidney
204 diseases. Additional information on the quality control procedures implemented in this
205 study have been described in the **Supplementary Methods**.

206 **2.8 Statistical analysis**

207 Baseline characteristics of the study population are presented across quartiles of hPDI and
208 uPDI scores. Continuous variables are presented as mean \pm standard deviation (SD) and
209 categorical variables are presented as a number and percentage proportion. Associations
210 between PDIs and total mortality were examined using Cox proportional hazards regression
211 models, with age (years) as the timescale. Results are reported as hazard ratios (HRs) and
212 95% confidence intervals (95% CI). Linear trend tests involved modelling the PDIs as
213 continuous exposure variables (P_{trend}). The proportional hazards assumption was tested by
214 the Schoenfeld residual method. Analyses were adjusted for confounding factors using two
215 models. Model 1 was adjusted for sex (female, male) and education (Low: CSEs or
216 equivalent, O levels/GCSEs or equivalent; Medium: A levels/AS levels or equivalent, NVQ or
217 HND or HNC or equivalent; High: College or University degree, other professional
218 qualifications eg: nursing, teaching; unknown/missing/prefer not to say (15.6%)), stratified
219 by age (5-year categories) and geographical region of recruitment (ten UK regions). Model 2
220 was additionally adjusted for BMI (18.5-24.9 kg/m², 25.0-29.9 kg/m², \geq 30 kg/m², or
221 unknown/missing (0.4%)), waist circumference (continuous scale, cm), ethnicity (Asian,
222 Black, Multiple, White, other/unknown/missing (1.3%)), physical activity (Metabolic
223 Equivalent Tasks (METs) hr/week in quintiles, or unknown/missing (2.7%)), smoking status
224 (never, previous, current, or unknown/missing (0.3%)), alcohol intake (continuous scale,
225 g/day), energy intake (continuous scale, kJ/day), multimorbidity index (number of pre-
226 existing long-term conditions at baseline; 0, 1, 2, or >3), polypharmacy index (total number
227 of self-reported medications take at baseline; 0, 1-3, 4-6, 7-9, >10), Townsend deprivation
228 index (quintiles from low to high deprivation), prevalent diabetes (no, yes), protein intake
229 (continuous, g/day) and number of completed dietary assessments (continuous scale,

230 ranging between 1-5). In addition to main analyses, multivariable Cox regression analyses
231 were performed for each of the 17 PDI food groups.

232 To investigate whether associations between the continuous hPDI and uPDI (10-point
233 increments) and risk of mortality differed by population groups, analyses were stratified by
234 age (<63 or ≥63 years), sex (male or female), smoking status (never or ever), alcohol intake
235 (tertiles from low to high alcohol intake: low [$<1\text{g/day}$], moderate [$1\text{-}\leq 14\text{g/day}$] or high
236 [$\geq 15\text{g/day}$]), protein intake (<median [$<77\text{g/day}$] or ≥ median [$\geq 77\text{g/day}$]), eGFR (<35
237 mL/min/1.73 m² or ≥35 mL/min/1.73 m²), PRS (tertiles from low to high PRS for eGFR) and
238 CKD stage (stage 1-2, stage 3a-3b, or stage 4-5), testing for interactions using likelihood ratio
239 tests (LRT). To assess the robustness of our findings, three further sets of analyses were
240 conducted. Firstly, primary analyses were further adjusted for eGFR to account for level of
241 kidney function. Secondly, primary analyses were further adjusted for genetic susceptibility
242 to kidney diseases (PRS of eGFR). Thirdly, analyses were restricted to participants who had
243 completed ≥2 dietary assessments. Finally, to assess potential reverse causation bias,
244 sensitivity analyses were carried out excluding the first 2 years of follow-up.

245 Intraclass correlation coefficients (ICCs) were used to test the reliability of the PDIs over
246 time. PDI scores were calculated from mean food intakes at each Oxford WebQ dietary
247 assessment (cycle 0: April 2009 to September 2010 vs cycle 1: February 2011 to April 2011
248 vs cycle 2: June 2011 to September 2011 vs cycle 3: October 2011 to December 2011 vs
249 cycle 4: April 2012 to June 2012).

250 Statistical analyses were performed using Stata statistical software version 18.0 (StataCorp
251 LLC). Two-sided *P* values were considered statistically significant.

252 **3. Results**

253 **3.1 Study participants and baseline characteristics**

254 Baseline characteristics and nutrient intakes of 4,807 study participants with CKD are shown
255 across quartiles of hPDI and uPDI in **Table 1 and Supplementary Table S3-Table S5**. A
256 comparison of baseline characteristics of CKD patients with and without dietary data is
257 shown in **Supplementary Table S6**. The mean (SD) age was 60.9 (6.9), 2,452 (51.0%) were
258 female, 543 (11.3%) had prevalent diabetes, and the mean baseline eGFR was 59.5
259 mL/min/1.73m². Individuals with higher scores of hPDI were more likely to be women, have
260 a lower BMI, be more physically active and have a higher education level than those with
261 lower scores. Individuals with higher scores of uPDI were more likely to be men, have a
262 higher BMI, be less physically active and have a lower education level than those with lower
263 scores.

264 The ICCs (range) for reproducibility of the PDIs over time ranged from 0.48 (39-75) to 0.53
265 (45-79) for hPDI and 0.42 (42-72) to 0.48 (40-73) for uPDI, respectively (**Supplementary**
266 **Table S7**).

267 **3.2 Plant-based diets and mortality risk**

268 During a mean (IQR) follow-up of 10.4 (0.9) years, 675 participants died. In multivariable-
269 adjusted Cox regression models (Model 2), dose-response associations were shown for both
270 hPDI and uPDI with risk of mortality. Participants in the highest hPDI quartile (Quartile 4
271 (Q4)) had a 33% lower risk of mortality [HR_{Q4vsQ1} (95% CI): 0.67 (0.53-0.84); $p_{\text{trend}} = 0.001$]
272 compared to those in the lowest hPDI quartile (Quartile 1 (Q1)) (**Table 2**). In contrast,
273 participants in the highest uPDI quartile (Q4) had 49% higher risk of mortality [1.49 (1.18-
274 1.89); $p_{\text{trend}} = 0.004$] compared to those in the lowest uPDI quartile (Q1).

275 Of the individual PDI components, higher intakes (Q4) of wholegrains (>2.9 servings/day)
276 was associated with a 29% lower risk of mortality [HR_{Q4vsQ1} (95% CI): 0.71 (0.56-0.90), p_{trend}
277 = 0.02] compared to lower intakes (Q1) (zero servings/day), while higher intakes (Q4) of
278 refined grains (2.0 servings/day) and SSBs (1.1 serving/day) was associated with a 28% and
279 31% higher risk of mortality [1.28 (1.04-1.59), p_{trend} = 0.002; 1.31 (1.06-1.62), p_{trend} = 0.001],
280 respectively, compared to lower intakes (Q1) (zero servings/day) (**Table 3**).

281 **3.3 Subgroup and sensitivity analyses**

282 For associations between hPDI and mortality, subgroup analysis showed no evidence of
283 heterogeneity across key covariates (age, sex, smoking status, alcohol intake, protein intake,
284 eGFR, PRS (eGFR), and CKD stage) (**Supplementary Table S8-S9**). Results remained robust in
285 sensitivity analyses: further adjusting for eGFR, genetic susceptibility of kidney diseases and
286 excluding participants with short follow-up duration (<2 years) (**Supplementary Tables S10-**
287 **S12**). Stronger associations were shown between hPDI and uPDI and mortality risk in repeat
288 analyses restricting to ≥ 2 dietary assessments, although P_{trend} for uPDI turned non-
289 significant (p_{trend} = 0.08) (**Supplementary Table S13**).

290

291

292

293

294

295 **4. Discussion**

296 In this large-scale cohort study, higher adherence to hPDI was associated with a 33% lower
297 risk of all-cause mortality among individuals with CKD, while a higher uPDI was associated
298 with a 49% higher risk following full adjustment for a range of diet and lifestyle factors.
299 Associations between PDIs and mortality were only shown for CKD patients in early stages
300 (stages 1-2).

301 Our findings support the role of adopting a healthy plant-based dietary pattern for
302 lengthening survival of CKD. While it's widely recognised that increased adherence to a PBD
303 may lower mortality risk in the general population (31-33), to our knowledge, only one
304 study currently exists on PBDs and risk of CKD progression and all-cause mortality in CKD
305 patients from the Chronic Renal Insufficiency Cohort (CRIC) Study (34). While it's reassuring
306 to find that our results align with those from the CRIC study, one key difference to note is
307 that our study consisted mostly of individuals with early stage CKD (97% with CKD stages 1-
308 3b; mean (SD) eGFR of 59.5 (18.0)), while the CIRC study was predominantly made up of
309 CKD patients with stages 3 and 4 (70% and 18% respectively; mean (SD) eGFR of 43.4 (13.5))
310 (35)). Collectively, these findings suggest that a healthful PBD exerts benefits across all
311 stages of CKD, in line with previous studies to suggest that higher dietary intake of healthful
312 plant foods lowers CKD risk through improved kidney function (36-38).

313 Several plausible biological mechanisms may explain the beneficial role of plant-rich diets on
314 kidney health. Firstly, plant-rich diets are typically nutrient dense, providing a rich source of
315 vitamins, minerals, and phytochemicals. Flavonoids, a group of secondary plant metabolites
316 have shown to have renoprotective effects in CKD through their anti-inflammatory and
317 antioxidant properties (39, 40). Supporting this, a randomized, double-blinded, placebo-

318 controlled trial previously reported dietary cocoa flavanols to improve vascular function in
319 patients with ESKD (41). Our study also revealed that individuals with a higher hPDI
320 consumed 39% more dietary fibre than those with a low hPDI. A recent meta-analysis of 10
321 cohort studies indicated the potential protective effects of increasing dietary fibre
322 consumption against all-cause mortality, cardiovascular mortality and cardiovascular disease
323 in CKD patients (42). Moreover, previous research has demonstrated that increased dietary
324 fibre intake is likely to reduce levels of inflammation in CKD patients (43-45). Results from
325 an intervention trial demonstrated significantly lower levels of C-reactive protein,
326 interleukin-6, interleukin-8, and tumour necrosis factor- α in haemodialysis patients
327 supplemented with 10g and 20g of dietary fibre per day over 6 weeks (46). Further, through
328 increased intestinal motility, dietary fibre has also been shown to play a favourable role in
329 the gut microbiome, promoting the growth of beneficial microbiota, and decreasing uremic
330 toxin production (47, 48). Supporting this, a meta-analysis of 14 controlled feeding trials
331 revealed that greater dietary fibre intake was associated with lower serum urea and
332 creatinine levels in individuals with CKD (49).

333 PBDs typically confer lower intakes of animal-based foods. Though the exact mechanisms
334 through which animal foods such as red meat may contribute to renal toxicity are unclear,
335 one proposed explanation is that increased consumption of animal foods leads to a high
336 acid load in the diet (50). Higher acid load in the diet has been linked to renal toxicity and
337 kidney function decline through metabolic acidosis in patients with CKD (51). It is also
338 inferred that animal foods increase inflammation and promote unfavourable changes to the
339 gut microbiome which lead to increased production of uremic toxins (52-54), potentially
340 influencing the progression of renal disease. Although in this study, no significant
341 associations were shown for higher meat intake and reduced mortality, evidence from the

342 Nurses' Health Study suggests that consuming two or more servings of red meat per week
343 increases the risk of microalbuminuria (55), while the Singapore Chinese Health Study found
344 a dose-dependent relationship between red meat intake and ESKD (56). In addition, a
345 randomized crossover trial of postmenopausal women demonstrated that replacing meat
346 with soy improved insulin sensitivity, offering a potential approach for managing and
347 preventing metabolic syndrome (57)—a pathological state associated with decreased renal
348 function (58, 59).

349 Our study also showed that higher intakes of SSBs were associated with increased mortality
350 risk. While our findings align with those of a recent dose-response meta-analysis where
351 greater consumption of SSBs was associated with a higher risk of all-cause mortality (60),
352 numerous other studies have also observed that a higher intake of sugar or artificially
353 sweetened beverages was associated with kidney function decline (61-63). Some possible
354 biological mechanisms that may explain these associations include that SSBs contain high
355 amounts of added sugar and lead to low satiety, contributing to weight gain and obesity (64,
356 65). Moreover, SSBs often contain high levels of fructose which has previously been linked
357 to renal disease and its progression through hyperuricemia (66, 67) and kidney stone
358 formation (68).

359 **4.1 Limitations**

360 There are some limitations of this study. Firstly, despite our efforts to account for various
361 potential confounding factors, unmeasured or residual confounding could still be present
362 given the observational design of the study, so results should be interpreted with caution.
363 Secondly, the PDI was based on self-reported 24-hr dietary data, introducing the possibility
364 of measurement error and recall bias. Thirdly, this study was confined to individuals with

365 pre-existing CKD; to maximise the sample size, participants with data from at least one 24-h
366 dietary assessment were included (2,118 (44.1%) of 4,807 completed one dietary
367 assessment). While a single dietary assessment limits the reproducibility of food group level
368 intakes, this study, in addition to others, has shown that diet quality scores including the
369 PDIs are reproducible over time based on single dietary recalls (21, 69, 70). Fourthly,
370 primary care data was not used to identify CKD cases, potentially constraining the sample
371 size of this study. Despite this, eGFR was also used to classify patients with CKD, which is
372 considered an optimal marker of kidney function (71). Finally, subgroup analyses by
373 ethnicity were not conducted due to the limited number of non-white participants in the
374 study (344 (7.2%) of 4,807), further highlighting that the UK Biobank is not representative of
375 the UK population, limiting the generalisability of our findings (72).

376

377 **5. Conclusion**

378 In conclusion, better adherence to a healthy PBD was associated with a lower risk of all-
379 cause mortality independent of a wide range of factors, including eGFR and genetic
380 susceptibility to kidney diseases, while higher adherence to an unhealthy PBD was
381 associated with a higher risk. While existing recommendations for nutritional management
382 of CKD primarily target individual dietary components i.e., protein and sodium (71, 73), our
383 data support the shift towards healthy plant-based dietary patterns, specifically through
384 increasing intakes of wholegrains and lowering intakes of refined grains and sugar-
385 sweetened beverages, to better manage and treat CKD patients. Our findings underscore
386 the importance of conducting large-scale clinical trials to further explore the impact of
387 plant-based dietary patterns on clinical outcomes among individuals with CKD.

388

389 **Funding statement:** This research was conducted using UK Biobank funded and sourced
390 data (application 64426). The UK Biobank was established by the Wellcome Trust, the
391 Medical Research Council, the UK Department of Health, and the Scottish Government. The
392 UK Biobank has also received funding from the Welsh Assembly Government, the British
393 Heart Foundation, and Diabetes United Kingdom, Northwest Regional Development Agency,
394 Scottish Government. In addition, Alysha S. Thompson holds a PhD studentship of the
395 Department for the Economy (DfE), Northern Ireland. This work was in part supported by
396 the Co-Centre for Sustainable and Resilient Food Systems.

397 **Conflict of interest:** None were reported.

398 **Authors' contributions:** Design and concept: AT, TK, AC; database development: AT, ATR,
399 JKO, CH; analysed and interpreted data: AT, AC, TK; drafted manuscript: AT, TK, AC; provided
400 critical review of the manuscript: all authors; guarantors of the work: AT and TK.

401 **Data sharing statement:** UK Biobank data can be requested by all bona fide researchers for
402 approved projects, including replication, through <https://www.ukbiobank.ac.uk/>. This
403 research was conducted using UK Biobank funded and sourced data (application 64426).

404 **Ethics statement:** All UK Biobank participants provided informed consent to participate and
405 be followed through linkage to their health records. The UK Biobank study received ethical
406 approval from the NHS North West Multicentre Research Ethics Committee (Ref.
407 11/NW/0382).

408 Disclaimer: "The views expressed in this publication are those of the authors and should not
409 be interpreted as representing the official position of the European Food Safety Authority
410 (EFSA). Therefore, the present article is published under the sole responsibility of the

411 authors, and may not be considered as an EFSA scientific output. EFSA cannot be held
412 accountable for any errors or inaccuracies that may appear."

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431 **References**

- 432 1. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al.
433 Global, regional, and national burden of chronic kidney disease, 1990–2017: a
434 systematic analysis for the Global Burden of Disease Study 2017. *The lancet*.
435 2020;395(10225):709-33.
- 436 2. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey
437 M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-
438 specific mortality for 250 causes of death: reference and alternative scenarios
439 for 2016-40 for 195 countries and territories. *Lancet*. 2018;392(10159):2052-
440 90.
- 441 3. Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, et al. Analysis of the
442 Global Burden of Disease study highlights the global, regional, and national
443 trends of chronic kidney disease epidemiology from 1990 to 2016. *Kidney*
444 *International*. 2018;94(3):567-81.
- 445 4. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al.
446 Global burden of 369 diseases and injuries in 204 countries and territories,
447 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.
448 *The lancet*. 2020;396(10258):1204-22.
- 449 5. Levey AS, Coresh J. Chronic kidney disease. *The lancet*.
450 2012;379(9811):165-80.
- 451 6. Levin A, Tonelli M, Bonventre J, Coresh J, Donner J-A, Fogo AB, et al.
452 Global kidney health 2017 and beyond: a roadmap for closing gaps in care,
453 research, and policy. *The Lancet*. 2017;390(10105):1888-917.
- 454 7. Jha V, Al-Ghamdi SM, Li G, Wu M-S, Stafylas P, Retat L, et al. Global
455 Economic Burden Associated with chronic kidney disease: a pragmatic review
456 of medical costs for the Inside CKD Research Programme. *Advances in Therapy*.
457 2023;40(10):4405-20.
- 458 8. Kefale B, Alebachew M, Tadesse Y, Engidawork E. Quality of life and its
459 predictors among patients with chronic kidney disease: A hospital-based cross
460 sectional study. *PLOS ONE*. 2019;14(2):e0212184.
- 461 9. Kelly JT, Palmer SC, Wai SN, Ruospo M, Carrero J-J, Campbell KL, et al.
462 Healthy dietary patterns and risk of mortality and ESRD in CKD: a meta-analysis
463 of cohort studies. *Clinical journal of the American Society of Nephrology*:
464 *CJASN*. 2017;12(2):272.

- 465 10. González-Ortiz A, Xu H, Avesani CM, Lindholm B, Cederholm T, Risérus U,
466 et al. Plant-based diets, insulin sensitivity and inflammation in elderly men with
467 chronic kidney disease. *Journal of Nephrology*. 2020;33(5):1091-101.
- 468 11. Yuzbashian E, Asghari G, Mirmiran P, Amouzegar-Bahambari P, Azizi F.
469 Adherence to low-sodium Dietary Approaches to Stop Hypertension-style diet
470 may decrease the risk of incident chronic kidney disease among high-risk
471 patients: a secondary prevention in prospective cohort study. *Nephrology
472 Dialysis Transplantation*. 2018;33(7):1159-68.
- 473 12. Tyson CC, Davenport CA, Lin P-H, Scialla JJ, Hall R, Diamantidis CJ, et al.
474 DASH diet and blood pressure among black Americans with and without CKD:
475 the Jackson Heart Study. *American Journal of Hypertension*. 2019;32(10):975-
476 82.
- 477 13. Joshi S, Shah S, Kalantar-Zadeh K. Adequacy of plant-based proteins in
478 chronic kidney disease. *Journal of Renal Nutrition*. 2019;29(2):112-7.
- 479 14. Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero J-J, Chan
480 W, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update.
481 *American Journal of Kidney Diseases*. 2020;76(3, Supplement 1):S1-S107.
- 482 15. Kistler BM, Moore LW, Benner D, Biruete A, Boaz M, Brunori G, et al. The
483 International Society of Renal Nutrition and Metabolism Commentary on the
484 National Kidney Foundation and Academy of Nutrition and Dietetics KDOQI
485 Clinical Practice Guideline for Nutrition in Chronic Kidney Disease. *J Ren Nutr*.
486 2021;31(2):116-20.e1.
- 487 16. Anderson CAM, Nguyen HA, Rifkin DE. Nutrition Interventions in Chronic
488 Kidney Disease. *Medical Clinics of North America*. 2016;100(6):1265-83.
- 489 17. Yan B, Su X, Xu B, Qiao X, Wang L. Effect of diet protein restriction on
490 progression of chronic kidney disease: A systematic review and meta-analysis.
491 *PLoS One*. 2018;13(11):e0206134.
- 492 18. Ko GJ, Rhee CM, Kalantar-Zadeh K, Joshi S. The Effects of High-Protein
493 Diets on Kidney Health and Longevity. *J Am Soc Nephrol*. 2020;31(8):1667-79.
- 494 19. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK
495 biobank: an open access resource for identifying the causes of a wide range of
496 complex diseases of middle and old age. *PLoS medicine*. 2015;12(3):e1001779-
497 e.
- 498 20. Schofield WN, Schofield C, James WPT. Basal metabolic rate: review and
499 prediction, together with an annotated bibliography of source material. 1985.

- 500 21. Perez-Cornago A, Pollard Z, Young H, van Uden M, Andrews C, Piernas C,
501 et al. Description of the updated nutrition calculation of the Oxford WebQ
502 questionnaire and comparison with the previous version among 207,144
503 participants in UK Biobank. *European Journal of Nutrition*. 2021;60(7):4019-30.
- 504 22. Greenwood DC, Hardie LJ, Frost GS, Alwan NA, Bradbury KE, Carter M, et
505 al. Validation of the Oxford WebQ Online 24-Hour Dietary Questionnaire Using
506 Biomarkers. *Am J Epidemiol*. 2019;188(10):1858-67.
- 507 23. Galante J, Adamska L, Young A, Young H, Littlejohns TJ, Gallacher J, et al.
508 The acceptability of repeat Internet-based hybrid diet assessment of previous
509 24-h dietary intake: administration of the Oxford WebQ in UK Biobank. *British*
510 *Journal of Nutrition*. 2016;115(4):681-6.
- 511 24. Liu B, Young H, Crowe FL, Benson VS, Spencer EA, Key TJ, et al.
512 Development and evaluation of the Oxford WebQ, a low-cost, web-based
513 method for assessment of previous 24 h dietary intakes in large-scale
514 prospective studies. *Public Health Nutr*. 2011;14(11):1998-2005.
- 515 25. Satija A, Bhupathiraju SN, Rimm EB, Spiegelman D, Chiuve SE, Borgi L, et
516 al. Plant-Based Dietary Patterns and Incidence of Type 2 Diabetes in US Men
517 and Women: Results from Three Prospective Cohort Studies. *PLOS Medicine*.
518 2016;13(6):e1002039.
- 519 26. Satija A, Bhupathiraju SN, Spiegelman D, Chiuve SE, Manson JE, Willett
520 W, et al. Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary
521 Heart Disease in U.S. Adults. *Journal of the American College of Cardiology*.
522 2017;70(4):411-22.
- 523 27. Heianza Y, Zhou T, Sun D, Hu FB, Qi L. Healthful plant-based dietary
524 patterns, genetic risk of obesity, and cardiovascular risk in the UK biobank
525 study. *Clinical Nutrition*. 2021;40(7):4694-701.
- 526 28. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro III AF, Feldman HI, et
527 al. A new equation to estimate glomerular filtration rate. *Annals of internal*
528 *medicine*. 2009;150(9):604-12.
- 529 29. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The
530 UK Biobank resource with deep phenotyping and genomic data. *Nature*.
531 2018;562(7726):203-9.
- 532 30. Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, et al. A catalog of
533 genetic loci associated with kidney function from analyses of a million
534 individuals. *Nature genetics*. 2019;51(6):957-72.
- 535 31. Jafari S, Hezaveh E, Jalilpiran Y, Jayedi A, Wong A, Safaiyan A, et al. Plant-
536 based diets and risk of disease mortality: a systematic review and meta-

- 537 analysis of cohort studies. *Critical Reviews in Food Science and Nutrition*.
538 2022;62(28):7760-72.
- 539 32. Li H, Zeng X, Wang Y, Zhang Z, Zhu Y, Li X, et al. A prospective study of
540 healthful and unhealthful plant-based diet and risk of overall and cause-
541 specific mortality. *European Journal of Nutrition*. 2022;61(1):387-98.
- 542 33. Shan Z, Wang F, Li Y, Baden MY, Bhupathiraju SN, Wang DD, et al.
543 Healthy eating patterns and risk of total and cause-specific mortality. *JAMA*
544 *internal medicine*. 2023;183(2):142-53.
- 545 34. Amir S, Kim H, Hu EA, Ricardo AC, Mills KT, He J, et al. Adherence to
546 Plant-Based Diets and Risk of CKD Progression and All-Cause Mortality:
547 Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. *American*
548 *Journal of Kidney Diseases*. 2023.
- 549 35. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, et al. Chronic Renal
550 Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with
551 kidney function. *Clinical Journal of the American Society of Nephrology*.
552 2009;4(8):1302-11.
- 553 36. Kim H, Caulfield LE, Garcia-Larsen V, Steffen LM, Grams ME, Coresh J, et
554 al. Plant-Based Diets and Incident CKD and Kidney Function. *Clin J Am Soc*
555 *Nephrol*. 2019;14(5):682-91.
- 556 37. Haring B, Selvin E, Liang M, Coresh J, Grams ME, Petruski-Ivleva N, et al.
557 Dietary protein sources and risk for incident chronic kidney disease: results
558 from the Atherosclerosis Risk in Communities (ARIC) Study. *Journal of Renal*
559 *Nutrition*. 2017;27(4):233-42.
- 560 38. Oosterwijk MM, Soedamah-Muthu SS, Geleijnse JM, Bakker SJ, Navis G,
561 Binnenmars SH, et al. High dietary intake of vegetable protein is associated
562 with lower prevalence of renal function impairment: results of the Dutch
563 DIALECT-1 cohort. *Kidney international reports*. 2019;4(5):710-9.
- 564 39. de Almeida Alvarenga L, Borges NA, Moreira LdSG, Teixeira KTR, Carraro-
565 Eduardo JC, Dai L, et al. Cranberries—potential benefits in patients with chronic
566 kidney disease. *Food & function*. 2019;10(6):3103-12.
- 567 40. Vargas F, Romecín P, García-Guillén AI, Wangesteen R, Vargas-Tendero
568 P, Atucha NM, et al. Flavonoids in kidney health and disease. *Frontiers in*
569 *physiology*. 2018;9:350109.
- 570 41. Rassaf T, Rammos C, Hendgen-Cotta UB, Heiss C, Kleophas W, Dellanna
571 F, et al. Vasculoprotective effects of dietary cocoa flavanols in patients on
572 hemodialysis: a double-blind, randomized, placebo-controlled trial. *Clinical*
573 *Journal of the American Society of Nephrology*. 2016;11(1):108-18.

- 574 42. Gai W, Lin L, Wang Y, Bian J, Tao Y. Relationship between dietary fiber
575 and all-cause mortality, cardiovascular mortality, and cardiovascular disease in
576 patients with chronic kidney disease: a systematic review and meta-analysis.
577 *Journal of Nephrology*. 2024.
- 578 43. Xu H, Huang X, Riserus U, Krishnamurthy VM, Cederholm T, Ärnlöv J, et
579 al. Dietary fiber, kidney function, inflammation, and mortality risk. *Clinical*
580 *journal of the American Society of Nephrology: CJASN*. 2014;9(12):2104.
- 581 44. Krishnamurthy VMR, Wei G, Baird BC, Murtaugh M, Chonchol MB,
582 Raphael KL, et al. High dietary fiber intake is associated with decreased
583 inflammation and all-cause mortality in patients with chronic kidney disease.
584 *Kidney international*. 2012;81(3):300-6.
- 585 45. Veronese N, Solmi M, Caruso MG, Giannelli G, Osella AR, Evangelou E, et
586 al. Dietary fiber and health outcomes: an umbrella review of systematic
587 reviews and meta-analyses. *Am J Clin Nutr*. 2018;107(3):436-44.
- 588 46. Xie L-M, Ge Y-Y, Huang X, Zhang Y-Q, Li J-X. Effects of fermentable
589 dietary fiber supplementation on oxidative and inflammatory status in
590 hemodialysis patients. *International journal of clinical and experimental*
591 *medicine*. 2015;8(1):1363.
- 592 47. Mafra D, Borges N, Alvarenga L, Esgalhado M, Cardozo L, Lindholm B, et
593 al. Dietary components that may influence the disturbed gut microbiota in
594 chronic kidney disease. *Nutrients*. 2019;11(3):496.
- 595 48. Camerotto C, Cupisti A, D'Alessandro C, Muzio F, Gallieni M. Dietary fiber
596 and gut microbiota in renal diets. *Nutrients*. 2019;11(9):2149.
- 597 49. Chiavaroli L, Mirrahimi A, Sievenpiper JL, Jenkins DJA, Darling PB. Dietary
598 fiber effects in chronic kidney disease: a systematic review and meta-analysis
599 of controlled feeding trials. *European Journal of Clinical Nutrition*.
600 2015;69(7):761-8.
- 601 50. Remer T, editor *Acid-Base In Renal Failure: influence of diet on acid-base*
602 *balance*. *Seminars in dialysis*; 2000: Wiley Online Library.
- 603 51. Banerjee T, Crews DC, Wesson DE, Tilea AM, Saran R, Ríos-Burrows N, et
604 al. High dietary acid load predicts ESRD among adults with CKD. *Journal of the*
605 *American Society of Nephrology*. 2015;26(7):1693-700.
- 606 52. Moraes C, Fouque D, Amaral ACF, Mafra D. Trimethylamine N-oxide
607 from gut microbiota in chronic kidney disease patients: focus on diet. *Journal*
608 *of Renal Nutrition*. 2015;25(6):459-65.

- 609 53. Ley SH, Sun Q, Willett WC, Eliassen AH, Wu K, Pan A, et al. Associations
610 between red meat intake and biomarkers of inflammation and glucose
611 metabolism in women. *The American journal of clinical nutrition*.
612 2014;99(2):352-60.
- 613 54. Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic
614 toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. *J Am Soc*
615 *Nephrol*. 2014;25(9):1897-907.
- 616 55. Lin J, Hu FB, Curhan GC. Associations of diet with albuminuria and kidney
617 function decline. *Clin J Am Soc Nephrol*. 2010;5(5):836-43.
- 618 56. Lew Q-LJ, Jafar TH, Koh HWL, Jin A, Chow KY, Yuan J-M, et al. Red meat
619 intake and risk of ESRD. *Journal of the American Society of Nephrology: JASN*.
620 2017;28(1):304.
- 621 57. van Nielen M, Edith Feskens JM, Rietman A, Siebelink E, Mensink M.
622 Partly Replacing Meat Protein with Soy Protein Alters Insulin Resistance and
623 Blood Lipids in Postmenopausal Women with Abdominal Obesity. *The Journal*
624 *of Nutrition*. 2014;144(9):1423-9.
- 625 58. Kawamoto R, Akase T, Ninomiya D, Kumagi T, Kikuchi A. Metabolic
626 syndrome is a predictor of decreased renal function among community-
627 dwelling middle-aged and elderly Japanese. *International Urology and*
628 *Nephrology*. 2019;51:2285-94.
- 629 59. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan
630 SD. Metabolic syndrome and kidney disease: a systematic review and meta-
631 analysis. *Clinical journal of the American Society of Nephrology: CJASN*.
632 2011;6(10):2364.
- 633 60. Qin P, Li Q, Zhao Y, Chen Q, Sun X, Liu Y, et al. Sugar and artificially
634 sweetened beverages and risk of obesity, type 2 diabetes mellitus,
635 hypertension, and all-cause mortality: a dose-response meta-analysis of
636 prospective cohort studies. *European Journal of Epidemiology*. 2020;35(7):655-
637 71.
- 638 61. Lin J, Curhan GC. Associations of sugar and artificially sweetened soda
639 with albuminuria and kidney function decline in women. *Clinical journal of the*
640 *American Society of Nephrology: CJASN*. 2011;6(1):160.
- 641 62. Saldana TM, Basso O, Darden R, Sandler DP. Carbonated beverages and
642 chronic kidney disease. *Epidemiology (Cambridge, Mass)*. 2007;18(4):501.
- 643 63. Shoham DA, Durazo-Arvizu R, Kramer H, Luke A, Vupputuri S, Kshirsagar
644 A, et al. Sugary soda consumption and albuminuria: results from the National

- 645 Health and Nutrition Examination Survey, 1999–2004. *PloS one*.
646 2008;3(10):e3431.
- 647 64. Malik VS, Pan A, Willett WC, Hu FB. Sugar-sweetened beverages and
648 weight gain in children and adults: a systematic review and meta-analysis. *The*
649 *American journal of clinical nutrition*. 2013;98(4):1084-102.
- 650 65. Te Morenga L, Mallard S, Mann J. Dietary sugars and body weight:
651 systematic review and meta-analyses of randomised controlled trials and
652 cohort studies. *BMJ (Clin Res Ed)* 346: e7492. 2012.
- 653 66. Kang D-H, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, et al. A
654 role for uric acid in the progression of renal disease. *Journal of the American*
655 *Society of Nephrology*. 2002;13(12):2888-97.
- 656 67. Zheng Z, Harman JL, Coresh J, Köttgen A, McAdams-DeMarco MA, Correa
657 A, et al. The dietary fructose: vitamin C intake ratio is associated with
658 hyperuricemia in african-american adults. *The Journal of Nutrition*.
659 2018;148(3):419-26.
- 660 68. Taylor E, Curhan G. Fructose consumption and the risk of kidney stones.
661 *Kidney international*. 2008;73(2):207-12.
- 662 69. Carter JL, Lewington S, Piernas C, Bradbury K, Key TJ, Jebb SA, et al.
663 Reproducibility of dietary intakes of macronutrients, specific food groups, and
664 dietary patterns in 211 050 adults in the UK Biobank study. *J Nutr Sci*.
665 2019;8:e34-e.
- 666 70. Thompson AS, Tresserra-Rimbau A, Karavasiloglou N, Jennings A,
667 Cantwell M, Hill C, et al. Association of Healthful Plant-based Diet Adherence
668 With Risk of Mortality and Major Chronic Diseases Among Adults in the UK.
669 *JAMA Network Open*. 2023;6(3):e234714-e.
- 670 71. Eknoyan G, Lameire N, Eckardt K, Kasiske B, Wheeler D, Levin A, et al.
671 KDIGO 2012 clinical practice guideline for the evaluation and management of
672 chronic kidney disease. *Kidney int*. 2013;3(1):5-14.
- 673 72. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al.
674 Comparison of sociodemographic and health-related characteristics of UK
675 Biobank participants with those of the general population. *Am J Epidemiol*.
676 2017;186(9):1026-34.
- 677 73. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US
678 commentary on the 2012 KDIGO clinical practice guideline for the evaluation
679 and management of CKD. *Am J Kidney Dis*. 2014;63(5):713-35.

680

681

682

683

Table 1. Baseline characteristics across quartiles (Q) of the healthful plant-based diet index in the UK Biobank (n=4,807)

Characteristics across hPDI	Participants, No. (%) ^a				
	Q1	Q2	Q3	Q4	Whole sample
Number of participants	1,309 (27.2)	1,239 (25.8)	1,131 (25.5)	1,128 (23.5)	4,807 (100.0)
Mortality cases	236 (18.0)	168 (13.6)	140 (12.4)	131 (11.6)	675 (14.0)
Healthful plant-based diet index, mean (SD)	49.7 (3.2)	55.6 (1.5)	59.5 (1.5)	64.9 (2.7)	57.1 (6.0)
Sex-Female	631 (48.2)	631 (50.9)	598 (52.9)	592 (52.5)	2,452 (51.0)
Age at recruitment (years), mean (SD)	60.1 (7.3)	61.1 (6.9)	61.5 (6.6)	61.3 (6.5)	60.9 (6.5)
BMI (kg/m²), mean (SD)	29.5 (5.8)	28.5 (4.9)	28.2 (5.0)	27.7 (4.7)	28.5 (5.2)
Waist circumference (cm), mean (SD)	96.9 (14.9)	93.9 (14.0)	93.1 (13.5)	91.9 (13.3)	94.0 (14.1)
Energy intake (kJ/day), mean (SD)	9125.7 (2298.2)	8370.9 (2107.8)	7997.0 (2139.7)	7810.8 (2118.5)	8357.1 (2229.9)
Physical activity (MET-h/wk), mean (SD)	28.6 (45.8)	28.2 (38.3)	29.4 (36.0)	33.8 (43.2)	29.9 (41.2)
Ethnicity					
Asian	47 (3.6)	46 (3.7)	43 (3.8)	37 (3.3)	173 (3.6)
Black	1 (0.1)	3 (0.2)	7 (0.6)	2 (0.2)	13 (0.3)
Multiple	41 (3.1)	46 (3.7)	32 (2.8)	39 (3.5)	158 (3.3)
White	1,205 (92.1)	1,130 (91.2)	1,034 (91.4)	1,033 (91.6)	4,402 (91.6)
Other/missing ^b	15 (1.2)	14 (1.1)	15 (1.3)	17 (1.5)	61 (1.3)
Education^c					
Low	332 (25.4)	282 (22.8)	280 (24.8)	257 (22.8)	1,152 (24.0)
Medium	211 (16.1)	200 (16.1)	177 (15.7)	199 (17.6)	787 (16.4)
High	522 (40.0)	548 (44.2)	515 (45.5)	531 (47.1)	2,116 (44.0)
Missing	244 (18.6)	208 (16.8)	159 (14.1)	141 (12.5)	752 (15.6)
Smoking status					
Never	670 (51.2)	666 (53.8)	571 (50.5)	597 (52.9)	2,504 (52.1)
Previous	527 (40.3)	497 (40.1)	500 (44.2)	466 (41.3)	1,990 (41.4)
Current	110 (8.4)	71 (5.7)	56 (5.0)	62 (5.5)	299 (6.2)
Missing	2 (0.2)	5 (0.4)	4 (0.6)	3 (0.3)	14 (0.3)
Alcohol intake (g/day), mean (SD)	13.4 (19.6)	13.5 (18.5)	13.6 (19.4)	12.3 (19.6)	13.2 (19.3)
Prevalent diabetes	168 (12.8)	136 (11.0)	112 (9.9)	127 (11.3)	543 (11.3)
Multimorbidity					
0 LTCs	361 (27.6)	343 (27.7)	333 (29.4)	334 (29.6)	1,371 (28.5)
1 LTC	315 (24.1)	317 (25.6)	317 (28.0)	293 (26.0)	1,242 (25.8)
2 LTCs	302 (23.1)	296 (23.9)	247 (21.8)	275 (24.4)	1,120 (23.3)
≥3 LTCs	331 (25.3)	283 (22.8)	234 (20.7)	226 (20.0)	1,074 (22.3)
eGFR (mL/min/1.73 m²), mean (SD)	58.9 (18.6)	59.2 (18.0)	58.7 (16.6)	61.3 (18.4)	59.5 (18.0)
Protein intake (g/day), mean (SD)	83.9 (25.0)	79.6 (22.6)	77.7 (23.6)	76.9 (22.4)	79.7 (23.6)
hPDI food item intake (portion/day)^d, mean (SD)					
Healthy plant food					
Whole grains	1.4 (1.4)	1.9 (1.6)	2.2 (1.6)	2.7 (1.7)	2.0 (1.6)
Fruit	1.5 (1.3)	1.9 (1.5)	2.3 (1.7)	3.1 (1.9)	2.2 (1.7)
Vegetables	1.6 (1.6)	2.0 (1.9)	2.5 (2.2)	3.4 (2.5)	2.4 (2.2)
Nuts	0.1 (0.2)	0.1 (0.3)	0.1 (0.3)	0.2 (0.5)	0.1 (0.4)
Legumes	0.2 (0.4)	0.3 (0.5)	0.4 (0.5)	0.6 (0.7)	0.4 (0.5)
Tea and coffee	3.8 (1.8)	4.1 (1.7)	4.5 (1.8)	4.8 (1.8)	4.3 (1.8)
Unhealthy plant food					
Refined grains	1.9 (1.5)	1.2 (1.2)	0.9 (1.1)	0.6 (0.9)	1.2 (1.3)
Potatoes	0.9 (0.7)	0.8 (0.7)	0.7 (0.6)	0.6 (0.6)	0.7 (0.6)
Sugar-sweetened beverages	1.0 (1.2)	0.6 (0.9)	0.4 (0.8)	0.3 (0.7)	0.6 (1.0)
Fruit juices	0.5 (0.6)	0.5 (0.6)	0.4 (0.6)	0.3 (0.6)	0.4 (0.6)
Sweets and desserts	2.0 (1.6)	1.6 (1.3)	1.3 (1.3)	0.9 (1.1)	1.5 (1.4)
Animal-derived food					

Animal fat	1.3 (1.4)	0.8 (1.2)	0.5 (1.0)	0.3 (0.7)	0.8 (1.2)
Dairy	1.2 (0.9)	1.1 (0.8)	1.0 (0.8)	0.9 (0.8)	1.0 (0.9)
Eggs	0.4 (0.6)	0.3 (0.5)	0.2 (0.5)	0.2 (0.4)	0.3 (0.5)
Fish or seafood	0.4 (0.5)	0.3 (0.5)	0.3 (0.5)	0.2 (0.4)	0.3 (0.5)
Meat	1.5 (1.1)	1.3 (1.0)	1.1 (0.9)	1.0 (0.8)	1.2 (1.0)
Miscellaneous animal-based foods	0.1 (0.4)	0.1 (0.2)	0.1 (0.3)	0.0 (0.2)	0.1 (0.3)

^aRelative frequencies (%) include missing values which may not equate to 100%.

^bOther includes any race or ethnic group not otherwise specified.

^cEducation was categorised as Low: CSEs or equivalent, O levels/GCSEs or equivalent; Medium: A levels/AS levels or equivalent, NVQ or HND or HNC or equivalent; High: College or University degree, other professional qualifications eg: nursing, teaching.

^dPortion sizes were specified as a “serving” in the Oxford WebQ tool.

Abbreviations: *Q*, quartile; *hPDI*, healthful plant-based diet index; *BMI*, body mass index; *MET*, metabolic equivalent task; *SD*, standard deviation; *LTC*, long term condition; *eGFR*, estimated glomerular filtration rate.

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

Table 2. Hazard ratios (95% confidence intervals) of mortality among all individuals with chronic kidney disease across sex-specific quartiles (Q) of the healthful plant-based diet index (hPDI) and unhealthy plant-based diet index (uPDI) (n=4,807)

hPDI	Q1	Q2	Q3	Q4	P-trend
Cases/total	236/1,309	168/1,239	140/1,131	131/1,128	
HR (95% CI)					
Model 1	1.00 ^a	0.71 (0.58-0.87)	0.64 (0.52-0.79)	0.61 (0.49-0.75)	<0.001
Model 2	1.00 ^a	0.78 (0.64-0.96)	0.73 (0.58-0.91)	0.67 (0.53-0.84)	<0.001
uPDI	Q1	Q2	Q3	Q4	P-trend
Cases/total	151/1,250	177/1,374	157/1,148	190/1,035	
HR (95% CI)					
Model 1	1.00 ^a	1.11 (0.89-1.38)	1.20 (0.96-1.50)	1.66 (1.34-2.07)	<0.001
Model 2	1.00 ^a	1.07 (0.86-1.34)	1.22 (0.96-1.54)	1.49 (1.18-1.89)	0.004

Model 1 adjusted for sex and education; stratified by age (5-year categories) and region.

Model 2: Model 1 plus BMI, waist circumference, ethnicity, physical activity, smoking status, alcohol intake, energy intake, multimorbidity index, polypharmacy, Townsend deprivation index, prevalent diabetes, total protein intake and number of completed dietary assessments.

P-trend is for linear trend.

^aReference categories.

Abbreviations: Q, quartile; hPDI, healthful plant-based diet index; uPDI, unhealthy plant-based diet index; BMI, Body Mass Index; HR, hazard ratio; CI, confidence interval.

701

702

703

704

705

706

707

708

709

710

Table 3. Hazard ratios (95% confidence intervals) of mortality across key food groups from the plant-based diet index (n=4,807)

	Food group intake quartiles				P-trend
	Q1	Q2	Q3	Q4	
Healthy Plant Foods					
Wholegrains					
Intake (servings/d) ^a	0 (0-0)	1.0 (0.1-1.4)	2.0 (1.5-2.9)	3.8 (2.9-11.0)	
Cases/total	130/685	189/1,375	178/1,369	178/1,378	
HR (95% CI) ^b	1.00 ^c	0.76 (0.60-0.96)	0.82 (0.65-1.05)	0.71 (0.56-0.90)	0.02
Fruit					
Intake (servings/d) ^a	0 (0-0)	1.0 (0.1-1.4)	2.0 (1.5-2.9)	3.8 (2.9-18.0)	
Cases/total	105/582	164/1,161	213/1,610	193/1,454	
HR (95% CI) ^b	1.00 ^c	0.88 (0.68-1.14)	0.87 (0.68-1.12)	0.86 (0.66-1.11)	0.49
Vegetables					
Intake (servings/d) ^a	0 (0-0)	1.0 (0.1-1.6)	2.3 (1.6-3.1)	4.5 (3.1-24.0)	
Cases/total	108/667	203/1,385	192/1,429	172/1,326	
HR (95% CI) ^b	1.00 ^c	1.08 (0.84-1.38)	1.06 (0.82-1.36)	1.05 (0.81-1.37)	0.44
Nuts					
Intake (servings/d) ^a	0 (0-0)	0.3 (0.1-0.3)	0.5 (0.4-0.7)	1.0 (0.8-4.0)	
Cases/total	577/3,888	39/350	27/293	32/276	
HR (95% CI) ^b	1.00 ^c	0.96 (0.68-1.35)	0.69 (0.46-1.02)	0.95 (0.66-1.37)	0.44
Legumes					
Intake (servings/d) ^a	0 (0-0)	0.3 (0.1-0.4)	0.5 (0.4-0.8)	1.0 (0.8-6.0)	
Cases/total	326/2,227	102/795	103/855	144/930	
HR (95% CI) ^b	1.00 ^c	0.96 (0.75-1.24)	0.91 (0.71-1.15)	0.99 (0.81-1.21)	0.57
Tea and coffee					
Intake (servings/d) ^a	0 (0-0)	3.0 (0.3-3.8)	4.5 (3.8-5.1)	6.0 (5.1-18.0)	
Cases/total	13/108	245/1,573	230/1,745	187/1,381	
HR (95% CI) ^b	1.00 ^c	1.16 (0.65-2.05)	0.98 (0.55-1.75)	0.97 (0.54-1.74)	0.05
Unhealthy Plant Foods					
Refined grains					
Intake (servings/d) ^a	0 (0-0)	0.5 (0.1-0.9)	1.0 (1.0-1.9)	2.8 (2.0-9.0)	
Cases/total	172/1,257	119/1,032	166/1,298	218/1,220	
HR (95% CI) ^b	1.00 ^c	1.08 (0.83-1.40)	0.97 (0.77-1.21)	1.28 (1.04-1.59)	0.002
Potatoes					
Intake (servings/d) ^a	0 (0-0)	0.5 (0.1-0.1)	1.0 (0.6-1.0)	1.5 (1.1-5.0)	
Cases/total	137/1,033	141/1,117	267/1,827	130/830	
HR (95% CI) ^b	1.00 ^c	1.12 (0.87-1.44)	1.13 (0.91-1.41)	1.21 (0.93-1.57)	0.38
Sugar-sweetened beverages					
Intake (servings/d) ^a	0 (0-0)	0.4 (0.1-0.6)	1.0 (0.6-1.0)	2.0 (1.1-7.0)	
Cases/total	318/2,524	97/759	118/758	142/766	
HR (95% CI) ^b	1.00 ^c	1.09 (0.86-1.39)	1.20 (0.97-1.50)	1.31 (1.06-1.62)	0.001
Fruit juices					
Intake (servings/d) ^a	0 (0-0)	0.3 (0.1-0.4)	0.5 (0.5-0.9)	1.0 (1.0-13.0)	

Cases/total	339/2,378	58/426	128/943	150/1,060	
HR (95% CI) ^b	1.00 ^c	1.12 (0.83-1.52)	1.09 (0.88-1.34)	1.02 (0.84-1.25)	0.55
Sweets and desserts					
Intake (servings/d) ^a	0 (0-0)	0.8 (0.1-1.1)	1.7 (1.1-2.1)	3.0 (2.1-9.0)	
Cases/total	131/930	177/1,525	172/1,177	195/1,175	
HR (95% CI) ^b	1.00 ^c	0.88 (0.70-1.12)	1.08 (0.84-1.38)	1.10 (0.85-1.43)	0.22
Animal-Derived Foods					
Animal fat					
Intake (servings/d) ^a	0 (0-0)	0.8 (0.1-1.0)	2.0 (1.1-2.0)	3.0 (2.1-11.0)	
Cases/total	368/2,818	107/780	105/694	95/515	
HR (95% CI) ^b	1.00 ^c	1.21 (0.97-1.52)	1.04 (0.83-1.30)	1.16 (0.92-1.48)	0.14
Dairy					
Intake (servings/d) ^a	0 (0-0)	0.5 (0.1-0.9)	1.0 (1.0-1.4)	2.0 (1.5-7.0)	
Cases/total	133/834	150/1,246	195/1,301	197/1,426	
HR (95% CI) ^b	1.00 ^c	0.88 (0.68-1.14)	1.04 (0.83-1.32)	0.91 (0.72-1.16)	0.61
Eggs					
Intake (servings/d) ^a	0 (0-0)	0.3 (0.1-0.4)	0.5 (0.5-0.9)	1.0 (1.0-5.0)	
Cases/total	418/3,037	44/445	90/564	123/761	
HR (95% CI) ^b	1.00 ^c	0.89 (0.63-1.25)	1.24 (0.96-1.59)	0.98 (0.80-1.22)	0.39
Fish and seafood					
Intake (servings/d) ^a	0 (0-0)	0.3 (0.1-0.4)	0.5 (0.4-0.8)	1.0 (0.8-6.0)	
Cases/total	414/2,734	69/540	87/766	105/767	
HR (95% CI) ^b	1.00 ^c	1.11 (0.82-1.49)	0.91 (0.71-1.17)	1.03 (0.82-1.29)	0.94
Meat					
Intake (servings/d) ^a	0 (0-0)	0.5 (0.1-0.9)	1.0 (1.0-1.4)	2.0 (1.5-10.0)	
Cases/total	102/723	121/891	212/1,569	240/1,624	
HR (95% CI) ^b	1.00 ^c	1.31 (0.98-1.75)	1.17 (0.90-1.50)	1.23 (0.94-1.61)	0.14
Miscellaneous animal-based foods					
Intake (servings/d) ^a	0 (0-0)	0.3 (0.1-0.4)	0.5 (0.5-0.8)	1.0 (1.0-4.0)	
Cases/total	621/4,428	14/110	18/109	22/160	
HR (95% CI) ^b	1.00 ^c	1.16 (0.67-2.02)	1.45 (0.90-2.35)	0.96 (0.62-1.49)	0.63

^aIntake values are median (range) and portion sizes were specified as a “serving” in the Oxford WebQ tool.

^bHazard Ratios with 95% Confidence Intervals (CI) adjusted for sex, BMI, waist circumference, ethnicity, physical activity, smoking status, education, alcohol intake, energy intake, multimorbidity index, polypharmacy, Townsend deprivation index, prevalent diabetes, total protein intake and number of completed dietary assessments; stratified by age (5-year categories) and region.

^cReference categories.

P-trend is for linear trend.

Abbreviations: Q, quartile; BMI, Body Mass Index; HR, hazard ratio; CI, confidence interval.